Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from zidovudine/lamivudine to emtricitabine/tenofovir disoproxil fumarate in virologically suppressed HIV patients on efavirenz
2004-002254-59Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine + tenofovir disoproxil, lamivudine + zidovudine and efavirenz in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Started Feb 2005; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxillamivudine + zidovudineefavirenz
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2004-002254-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002254-59.